



PTO/SB/08b (08-03)
Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituta for form 1449B/PTO				Complete if Known	
				Application Number	10/668767
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	September 23, 2003
				First Named Inventor	Steven Gutteridge Et. Al.
				Art Unit	UNKNOWN 1646
				Examiner Name	UNKNOWN Ruixiang Li
				Attorney Docket Number	BB1533USNA
Sheet	1	of	8		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	1	CHRISTOPHER H. GEORGE ET AL., Ryanodine Receptor Mutations Associated With Stress-Induced Ventricular Tachycardia Mediate Increased Calcium Release in Stimulated Cardiomyocytes, Circ. Res. 93:531-540, 2003	<input type="checkbox"/>
↓	2	KINYA OTSU ET AL., Chromosome Mapping of Five Human Cardiac and Skeletal Muscle Sarcoplasmic Reticulum Protein Genes, Genomics, 17:507-509, 1993	<input type="checkbox"/>
	3	GIUSEPPE GIANNINI ET AL., The Ryanodine Receptor/Calcium Channel Genes are Widely and Differentially Expressed in Murine Brain and Peripheral Tissues, The Journal of Cell Biology, 128(5):893-904, 1995	<input type="checkbox"/>
	4	DAWEI JIANG ET AL., Enhanced Basal Activity of a Cardiac Ca ²⁺ Release channel (Ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death, Circulation Research, 91:218-225, 2002	<input type="checkbox"/>
	5	XUEHONG XU ET AL., Molecular Cloning of cDNA Encoding a Drosophila Ryanodine Receptor and Functional Studies of the Carboxyl-Terminal Calcium Release Channel, Biophysical Journal, 78:1270-1281, 2000	<input type="checkbox"/>
RLi	6	HIROSHI TAKESHIMA ET AL., Ca ²⁺ -induced Ca ²⁺ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor, The EMBO Journal 14(13):2999-3006, 1995	<input type="checkbox"/>

Examiner Signature	Ruixiang Li	Date Considered	4/26/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 08/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/668767
		Filing Date	September 23, 2003
		First Named Inventor	Steven Gutteridge Et. Al.
		Art Unit	UNKNOWN 1646
		Examiner Name	UNKNOWN RuiXiang Li
		Attorney Docket Number	BB1533USNA
Sheet	2	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	7	STEVEN O. MARX ET AL., PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor): Defective Regulation in Failing Hearts, Cell, Vol. 101:365-376, 2000	<input type="checkbox"/>
↓	8	ANDREW J. DINSMORE ET AL., Characterisation of Antibody Models of the Ryanodine Receptor for Use in High-Throughput Screening, Pestic Sci., Vol. 54:345-352, 1998	<input type="checkbox"/>
	9	TOSHIAKI IMAGAWA ET AL., Expression of Ca ²⁺ -Induced Ca ²⁺ Release Channel Activity from Cardiac Ryanodine Receptor cDNA in Chinese Hamster Ovary Cells, J. Biochem., Vol: 112:508-513, 1992	<input type="checkbox"/>
	10	BARBARA BRUCE ET AL., Screening for Ryanodine Receptor Type 2 Mutations in Families with Effort-Induced Polymorphic Ventricular Arrhythmias and Sudden Death, J. of Amer. Coll. of Card. Vol. 40(2):341-349, 2002	<input type="checkbox"/>
	11	GIAN ANTONIO DANELLI ET AL., Genetics of arrhythmogenic right ventricular cardiomyopathy, Current Opinion in Cardiology, Vol. 17:218-221, 2002	<input type="checkbox"/>
	RLi	12	MIEKO SHIWA ET AL., Molecular Cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs, Am. J. Physiol. Reg. Integrative Comp., Vol. 282:R727-R737, 2002

Examiner Signature	Ruixiang Li	Date Considered	4/25/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/668787		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN 1646		
		Examiner Name	UNKNOWN Ruixiang Li		
Sheet	3	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	13	YASUO OGAWA ET AL., Ryanodine Receptor Isoforms In Excitation-Contraction Coupling, Adv. Biophys., Vol. 36:27-64, 1999	<input type="checkbox"/>
	14	G. LEES ET AL., Cell Culture Approaches to Invertebrate Neuroscience, Academic Press, New York, pp. 123-127, 1988	<input type="checkbox"/>
	15	TOSHIAKI IMAGAWA ET AL., Expression of Ca ²⁺ -Induced Ca ²⁺ Release Channel Activity from Cardiac Ryanodine Receptor cDNA in Chinese Hamster Ovary Cells, J. Biochem., Vol. 112:508-513, 1992	<input type="checkbox"/>
	16	MANJUNATHA B. BHAT ET AL., Functional Calcium release Channel Formed by the Carboxyl-Terminal Portion of Ryanodine Receptor, Biophysical J., Volume 73:1329-1338, 1997	<input type="checkbox"/>
	17	NATASCIA TISO ET AL., The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations, Biochem. & Biophys. Res. Comm., Vol. 299:594-598, 2002	<input type="checkbox"/>
RLi	18	ISAAC N. PESSAH ET AL., Calcium-Ryanodine Receptor Complex, The J. of Biol. Chem., Vol. 261(19):8643-8648, 1986	<input type="checkbox"/>


Examiner Signature	Ruixiang Li	Date Considered	4/25/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/668767		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN 1646		
		Examiner Name	UNKNOWN Ruixiang Li		
Sheet	4	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	19	ELISABETH LEHMBERG ET AL., Similarity of Insect and Mammalian Ryanodine Binding Sites, Pesticide Biochem. & Phys., 48:145-152, 1994	<input type="checkbox"/>
	20	HIROSHI TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster, FEBS Letters, 337:81-87, 1994	<input type="checkbox"/>
	21	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 456161, ACCESSION NO: D17389, MARCH 25, 1999, H. TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster	<input type="checkbox"/>
	22	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871446, ACCESSION NO: D45899, DECEMBER 25, 2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans	<input type="checkbox"/>
	23	YASUJI SAKUBE ET AL., An Abnormal ketamine Response in Mutants Defective in the Ryanodine Receptor Gene ryr-1 (unc-68) of Caenorhabditis elegans, J. Mol. Biol., 267:849-864, 1997	<input type="checkbox"/>
RLi	24	ELENA PUENTE ET AL., Identification of a polymorphic ryanodine receptor gene from Heliothis virescens (Lepidoptera: Noctuidae), Insect Biochem. & Mol. Biol., Vol. 30:335-347, 2000	<input type="checkbox"/>

Examiner Signature	Ruixiang Li	Date Considered	4/25/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/668767		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN- 1646		
		Examiner Name	UNKNOWN Ruixiang Li		
Sheet	5	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	25	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 17352471, ACCESSION NO: 476994, DECEMBER 10, 2003, M. D. ADAMS ET AL., The genome sequence of Drosophila Melanogaster	<input type="checkbox"/>
	26	MARK D. ADAMS ET AL., The Genome Sequence of Drosophila Melanogaster, Science, Vol. 287:2185-2195,, 2000	<input type="checkbox"/>
	27	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 21301556, ACCESSION NO: EAA17301, MAY 31, 2002, UNKNOWN AUTHOR, UNKNOWN TITLE	<input type="checkbox"/>
	28	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871447, ACCESSION NO: BAA08309, DECEMBER 25, 2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans	<input type="checkbox"/>
	29	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 18656155, ACCESSION NO: BAB84714, FEBRUARY 14, 2002, M. SHIWA ET AL., Molecular cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs	<input type="checkbox"/>
RLi	30	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 13569850, ACCESSION NO: NP076357, DECEMBER 21, 2003, H. MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors	<input type="checkbox"/>

Examiner Signature	Ruixiang Li	Date Considered	4/25/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 08/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/668767		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN 1646		
		Examiner Name	UNKNOWN Ruxiang Li		
Sheet	6	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	31	HARUKO MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors, FEBS Letters, Vol. 553:141-144, 2003	<input type="checkbox"/>
	32	PATRICK MOST ET AL., Transgenic Overexpression of the Ca2+-binding Protein S100A1 in the Heart Leads to Increased in Vivo Myocardial Contractile Performance, J. of Biol. Chem., Vol. 278(36):33809-33817, 2003	<input type="checkbox"/>
	33	HUANG-TIAN YANG ET AL., The ryanodine receptor modulates the spontaneous beating rate of cardiomyocytes during development, PNAS, Vol. 99(14):9225-9230, 2002	<input type="checkbox"/>
	34	ANNE-VALERIE FAURE ET AL., Developmental expression of the calcium release channels during early neurogenesis of the mouse cerebral cortex, European J. of Neuroscience, Vol. 14:1613-1622, 2001	<input type="checkbox"/>
	35	MINGCAI ZHAO ET AL., Molecular Identification of the Ryanodine Receptor Pore-forming Segment, J. of Biol. Chem., Vol. 274(37):25971-25974, 1999	<input type="checkbox"/>
RLi	36	HIROSHI TAKESHIMA ET AL., Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2, The EMBO J., Vol. 17(12):3309-3316, 1998	<input type="checkbox"/>

Examiner Signature	Ruxiang Li	Date Considered	4/25/2006
--------------------	------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/668767		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN 1646		
		Examiner Name	UNKNOWN Ruixiang Li		
Sheet	7	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	37	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1245376, ACCESSION NO: AAA93465, APRIL 2, 1996, J. NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel	<input type="checkbox"/>
	38	JUNICHI NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel, FEBS Vol. 271(1,2):169-177, 1990	<input type="checkbox"/>
	39	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 4506757, ACCESSION NO: NP001026, DECEMBER 23, 2003, C.H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes	<input type="checkbox"/>
	40	CHRISTOPHER H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes, J. of Biol. Chem., Vol. 278(31):28856-28864, 2003	<input type="checkbox"/>
	41	JING ZHANG ET AL., Three-dimensional Localization of Divergent Region 3 of the Ryanodine Receptor to the Clamp-shaped Structures Adjacent to the FKBP Binding Sites, J. Biol. Chem., Vol. 278(16):14211-14218, 2003	<input type="checkbox"/>
RLi	42	HARUKO MASUMIYA ET AL., Localization of the 12.6-kDa FK506-binding Protein (FKBP12.6) Binding Site to the NH2-terminal Domain of the Cardiac Ca ²⁺ Release Channel (Ryanodine Receptor), J. Biol. Chem., Vol. 278(6):3786-3792, 2003	<input type="checkbox"/>

Examiner Signature	Ruixiang Li	Date Considered	4/25/2006
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/688767		
		Filing Date	September 23, 2003		
		First Named Inventor	Steven Gutteridge Et. Al.		
		Art Unit	UNKNOWN 1646		
		Examiner Name	UNKNOWN — Ruxiang Li		
Sheet	8	of	8	Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	43	JIEFEI TONG ET AL., Caffeine and Halothane Sensitivity of Intracellular Ca ²⁺ Release is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease, J. Biol. Chem., Vol. 272(42):26332-26339, 1997	<input type="checkbox"/>
	44	S. R. WAYNE CHEN ET AL., Antibodies as Probes for Ca ²⁺ Activation Sites in the Ca ²⁺ Release Channel (Ryanodine Receptor) of Rabbit Skeletal Muscle Sarcoplasmic Reticulum, J. Biol. Chem., Vol. 268(18):13414-1421, 1993	<input type="checkbox"/>
	45	CELETTA CALLAWAY ET AL., Localization of the High and Low Affinity [3H]Ryanodine binding Sites on the Skeletal Muscle Ca ²⁺ Release Channel, J. Biol. Chem., Vol. 269(22):15876-15884, 1994	<input type="checkbox"/>
	46	MELANIE SCHMITT ET AL., Binding Sites for Ca ²⁺ -Channel Effectors and Ryanodine in Periplaneta americana - Possible Targets for New Insecticides, Pestic Science, Vol. 48:375-385, 1996	<input type="checkbox"/>
	47	RICHARD E.A. TUNWELL ET AL., The human cardiac muscle ryanodine receptor-calcium release channel: Identification, primary structure and topological analysis, Biochem. J. Vol. 318:477-487, 1996	<input type="checkbox"/>
RLi			<input type="checkbox"/>

Examiner Signature	Ruxiang Li	Date Considered	4/1/2004
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	STEVEN GUTTERIDGE
Group Art Unit	1645-1646
Examiner Name	UNKNOWN- Ruixiang L
Attorney Docket Number	BB1533USNA

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

4/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov, or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.